Bowen Hu

Bowen Hu

Auto-generated profile, based on publicly available information

Bowen Hu

Department of Urology, the People's Hospital of Longhua, the Affiliated Hospital of Southern Medical University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2022 in Cancer Medicine
Verified
Journal Article
Open access
GYGuangda Yuan
Guangda Yuan
BHBowen Hu
Bowen Hu
JMJun Ma
Jun Ma
CZChuanyu Zhang
Chuanyu Zhang
HXHongya Xie
Hongya Xie
BNBin Ni
Bin Ni
Objective: Aberrant epigenetic remodeling represents a molecular hallmark in lung adenocarcinoma (LUAD). We aim to investigate the biological roles of SETDB2 and its underlying associations with oxidative stress, providing therapeutic targets for individualized treatment of LUAD.Methods: Differential analysis was conducted via Limma package, and Kaplan–Meier analysis was performed with survival package. CCK‐8, cell proliferation assay, transwell assay, and in vivo assays were conducted to assess the function of SETDB2. Western blot assay, RT‐qPCR, and immunohistochemistry (IHC) were conducted to assess the expression levels of SETDB2/NRF2. Chromatin immunoprecipitation (ChIP) assay and ChIP‐qPCR were conducted to assess the epigenetic roles of SETDB2.Results: We found that SETDB2 expression is decreased in tumor samples versus normal tissues in TCGA‐LUAD cohort, LUAD‐EAS cohort, GSE72094 dataset, and independent Soochow‐LUAD dataset. Patients with low SETDB2 levels had a worse prognosis relative to those with high SETDB2. SETDB2 inhibition could significantly promote cell growth, migration ability, and stemness maintenance. Gene set enrichment analysis (GSEA) suggested that SETDB2 correlated with oxidative stress crosstalk and regulated NRF2 mRNA levels. ChIP assay suggested that SETDB2 mainly recruited the H3K9me3 enrichment at the NRF2 promoter region to suppress the mRNA levels of NRF2. Downregulated SETDB2 could activate NRF2 transcription and expression, thereby promoting its downstream targets, like NQO1, FTH1, and ME1. Functional experiments demonstrated that low SETDB2 allowed NRF2 to drive malignant processes of LUAD. SETDB2 overexpression attenuated the ability of NRF2 signaling to neutralize cellular reactive oxygen species (ROS) levels, leading to enhanced cell apoptosis. Overexpressed SETDB2 could inhibit tumor progression in vivo and further render LUAD cells sensitive to chemotherapy.Conclusions: In conclusion, these findings uncovered the suppressive role of SETDB2 in LUAD. SETDB2 negatively regulates NRF2 signaling to modulate tumor progression, which creates a therapeutic vulnerability in LUAD.



2 November 2022 in Research Square
Verified
Preprint
Open access
PDF file
BHBowen Hu
Bowen Hu
FSFeng Shu
Feng Shu
YLYan Liu
Yan Liu
JZJiaying Zhu
Jiaying Zhu
HWHaojie Wang
Haojie Wang
YDYingbo Dai
Yingbo Dai
Prolonged androgen deprivation therapy (ADT) in patients with prostate cancer can eventually lead to the development of castration-resistant prostate cancer (CRPC). Once CRPC occurs, the patient's prognosis will be extremely poor. This study explored the time to progression and the predictability of risk factors for CRPC progression based on clinical information and laboratory indicators. Among 159 prostate cancer patients initially treated with ADT, 90 patients were screened for inclusion. Patients progressed to CRPC after endocrine therapy enrolled in Group B, and others enrolled in Group A. Within Group B, they were divided into B1 and B2 Group Based on progression to CRPC within 18 months or not. Multi-factor logistic regression analysis showed that the time to PSA nadir (TTN) (P = 0.031) and serum lactate dehydrogenase (LDH) (P = 0.013) were significantly different between Group A and B. TTN (P < 0.001), LDH (P = 0.001) and platelet to lymphocyte ratio (PLR) (P = 0.005) were significantly different between Group B1 and B2. Kaplan-Meier survival analysis and log-rank tests showed that TTN, LDH and PLR were statistically significantly different in CRPC progression-free survival. The ROC curve showed that the predictive value of TTN (AUC 0.852) (95% CI 0.768–0.942, p < 0.001) was much higher than that of PLR (AUC 0.631) or LDH (0.647) and that the AUC value of TTN combined with PLR and LDH increased to 0.958 (95% CI 0.911–0.997, p < 0.001). In addition, TTN correlated with tumour M-stage and haemoglobin (Hb). In conclusion, we derived independent and combined predictors of early progression to CRPC in prostate cancer patients.

25 August 2023 in Research Square
Verified
Preprint
Open access
PDF file
BHBowen Hu
Bowen Hu
MYMinbo Yan
Minbo Yan
SHShuchang Huang
Shuchang Huang
HLHui liang
Hui liang
WLWenfei Lian
Wenfei Lian
Background The evidence suggests that the systemic inflammatory response may influence Prostate-specific antigen (PSA) concentrations. The relationship between platelet-to-lymphocyte ratio (PLR) and PSA, on the other hand, remains contradictory. As a result, we examined the relationship between PLR and PSA using the National Health and Nutrition Examination Survey (NHANES) database. Methods After the screening, 6,638 participants out of 52,195 in the NHANES survey from 2001 to 2010 were suitable for our study. The PLR was the independent variable in our study, and PSA was the dependent variable. Results The selected subjects in our study had an average age of 58.563 years (± 11.848 years). After controlling for covariates, the results showed that for everyone increase in PLR, the PSA concentration increased by 0.004 ng/mL (0.001, 0.007), and the difference was statistically significant. Furthermore, we created a smoothing curve based on a fully adjusted model to investigate the possibility of a linear relationship between PLR and PSA concentration. Conclusion PLR is independently and positively correlated with PSA in American men. Due to detection bias, the specificity of detecting asymptomatic prostate cancer improves in populations with low PLR, whereas in people with high PLR, it may predispose to over-diagnosis of asymptomatic prostate cancer.